Clinical trials
Pulmonary Artery Hypertension clinical trials
Below are recruiting pulmonary artery hypertension clinical trials, each written for real people, not researchers. We’re tracking 163 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06770023RecruitingPhase 1
Bridge to lung transplant with ECMO for right heart failure
This study tests a special heart-lung support machine (ECMO) for people waiting for a lung transplant whose heart is failing due to high blood pressure in the lungs. The machine helps rest the heart and lungs until transplant surgery.
Jacksonville, FloridaAges 18–80 - NCT06052072Enrolling by invitation
Heart failure trial testing nerve treatment for lung pressure
This trial tests a new treatment that uses a device to calm overactive nerves in the lung's blood vessels. It is for heart failure patients who also have high blood pressure in their lungs, to see if it can help them breathe easier and feel better.
Chicago, IllinoisAges 22–85 - NCT06331208Recruiting
Mechanisms of Lung Blood Vessel Problems in Heart Failure
This study looks at how heart failure affects blood vessels in the lungs. If you have heart failure with reduced pumping ability and need a heart catheterization, you may be able to join.
PragueAges 18 years+ - NCT04078243Recruiting
Trial setup and testing in adults with pulmonary hypertension
This study tests new “trial tools” and designs for running early research in people with pulmonary hypertension. If you qualify, you may be asked to do extra trial-related procedures to help researchers test the process safely and smoothly.
Sheffield, South YorkshireAges 18 years+ - NCT04898114RecruitingPhase 1/Phase 2
Inhaled magnesium and sildenafil for newborn lung blood pressure
This study tests whether breathing in magnesium sulfate and giving sildenafil can improve breathing and lung blood vessel pressure in newborns with persistent pulmonary hypertension. It may help newborns who are having trouble oxygenating despite being on a ventilator.
SohagAges 6 hours–3 days - NCT07311135Recruiting
Smartwatch Oxygen Accuracy in Pulmonary Hypertension
This study tests how well a smartwatch measures oxygen levels in people with pulmonary hypertension during a 6-minute walk. It could help find a simpler way to check oxygen at home.
GlasgowAges 18 years+ - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT05967299RecruitingPhase 1
IV ZMA001 study in healthy adults
This Phase 1 trial tests how an IV medicine called ZMA001 behaves in healthy people and checks for early safety. It may help future studies of the drug by confirming dosing and effects in people before testing in patients.
Bethesda, MarylandAges 18–60 - NCT07623525RecruitingPhase 1/Phase 2
DIAG723 study for hereditary hemorrhagic telangiectasia
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
Camperdown, New South WalesAges 18 years+ - NCT06274801RecruitingPhase 3
Long-term study of seralutinib for pulmonary arterial hypertension
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Fresno, CaliforniaAges 18–75 - NCT06649110RecruitingPhase 1/Phase 2
A study of LTP001 for healthy people and those with PAH
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
Scottsdale, ArizonaAges 18–100 - NCT04062565RecruitingPhase 3
Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Tucson, ArizonaAges 18 years+ - NCT05452889RecruitingEarly Phase 1
PET scan study in pulmonary hypertension related to scleroderma
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Pittsburgh, PennsylvaniaAges 18–75 - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70 - NCT06350032RecruitingPhase 3
Testing treprostinil safety in children with PAH
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
Vienna, State of ViennaAges Up to 18 years - NCT06476470Recruiting
Taiwan ILD registry for understanding lung disease
This registry is gathering information from people with different types of interstitial lung disease (ILD) across Taiwan. It aims to better understand the disease and improve future care.
TaichungAges 18 years+ - NCT06549452Recruiting
Mobile health app to help teens with pulmonary hypertension exercise
This trial tests whether a smartphone app can help adolescents with pulmonary hypertension stay active and improve their health. If you are a teen with stable PH and can use an activity tracker, this study may be a good fit.
Nashville, TennesseeAges 10–21 - NCT06567379Recruiting
Heart function study in pulmonary arterial hypertension
This trial uses special ultrasound imaging to look at how well the heart works in people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to understand heart changes before and after starting PAH treatment.
NancyAges 19 years+ - NCT06605794Recruiting
FreeFlow heart shunt for severe idiopathic pulmonary hypertension
This trial tests a new device called FreeFlow, which creates a small opening in the wall between the top chambers of the heart to relieve pressure. It is for people with severe idiopathic pulmonary hypertension who still have serious symptoms despite standard medications.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06753981Recruiting
Triple drug therapy for new PAH patients
This trial tests whether a combination of three medications works well and is safe for people newly diagnosed with pulmonary arterial hypertension (PAH) that is not low-risk. It aims to see if starting with triple therapy early can improve outcomes.
Jinan, ShandongAges 18–80 - NCT06865118Recruiting
Home management of heart issues in scleroderma
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
OsloAges 18 years+ - NCT06941441RecruitingPhase 3
Exercise and medicine study for pulmonary arterial hypertension
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
Seattle, WashingtonAges 18 years+ - NCT06968962Recruiting
Starting PAH treatment: one drug first or two drugs together?
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Hangzhou, ZhejiangAges 18–80 - NCT07245680RecruitingPhase 3
Testing two pills vs one for pulmonary hypertension with heart or metabolism issues
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Le Kremlin-BicêtreAges 18 years+
Hear when a new Pulmonary Artery Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary artery hypertension?
- Yes. Clin2 currently lists 163 recruiting pulmonary artery hypertension studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary artery hypertension trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary artery hypertension trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Pulmonary Hypertension (Diagnosis)
- Pulmonary Hypertension Due to Left Heart Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.